CIMA SCS May 2019: Denby Healthcare
The CIMA SCS pre-seen materials were released last week for the May SCS exam, it’s based around a healthcare company called “Denby Healthcare” – you can find the official pre-seen materials from CIMA here.
SCS Astranti May 2019 Course
The full SCS course from Astranti is really packed full of resources.
Complete pre-seen pack (pre-seen, strategic, industry analysis and top 10 issues)
- 3 x Full tuition videos
- 2 x Study texts
- 2 x Live Masterclasses (the keys to passing and revision masterclass)
- 3 x Full Mock Exams (based on Nov 18 scenario)
- Detailed marking and feedback
- Ethics Pack
- Pass Guarantee
Here is an hours preview video of the Astranti pre-seen analysis to whet your appetite.
Pre-Seen Analysis: Denby Healthcare
I’ve gone through the pre-seen analysis a couple of times and found a few interesting areas that caught my eye;
There wasn’t a huge amount of significance in the P&L and Balance Sheet of Denby or their competitors but the analysis of the Overseas revenue did catch my eye.
It dropped from 145m to 103m in 2018 and this is a concern, given that equates to a 30% drop in revenue in that segment.
There is also a link or indicator as to how to combat this decline in revenue.
The Keeland Daily News article mentions a football player who flew to Cornopia to have specialist care that was not available.
“The club’s doctor had recommended the hospital because it could offer specialist care that was not available in Keeland.”
Denby should start looking towards specialist care that is not available in other areas to increase their own overseas revenue. Identifying other regions weaknesses when it comes to private medical care could prove a lucrative avenue of income.
It’s mentioned a few times in the pre-seen analysis, staffing is a Critical Success Factor for Denby Healthcare and need to ensure they keep their best staff and attract the best in the medical profession.
“Staffing is most important element of patient care”
And this isn’t just restricted to the head doctors or surgeons but the pre-seen emphasizes the importance of staff at levels. Which makes sense for a private hospital. The competition is fierce so any added extra value that can be given to the patient will have an impact on the reputation of the hospital.
However, there is some reassurance that this recognized and actions are in place to help mitigate those risks.
There is also an opportunity here for Denby to take advantage of the increase in applications for Nurisng Degree’s mentioned in the news article at the end of the pre-seen.
Denby should be thinking of working alongside the tuition providers to provide a stream of qualified nurses straight into Denby before a competitor private hospital does.
Share Price Plummet
The share price drop in the last six months will be a major concern to shareholders and will need to be addressed.
The share price in November 2018 was around K$4 but now it’s closer to K$2 – what has caused the share price to drop so dramatically?
The geared and ungeared beta’s are both below 1.0 so the market sees a below average risk with Denby Healthcare, so what has caused the markets to react the way they have?
Furthermore, there will be increased scrutiny from the shareholders as there is a widespread shareholding that will need to be re-assured the company is heading the right direction and plans are afoot to increase the share price in the coming months and years.